Sorting nexin 1 (SNX1), a member of the sorting nexin family, has been implicated in various cellular processes, yet its role in ovarian cancer (OV) remains poorly characterized.
First-pass extracted concept
SNX1
Candidate: concept label1 source documents9 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
Sorting nexin 1
Evidence Snippets
Supporting Sources
Linked Claims
SNX1 overexpression shows a synergistic anti-tumor effect with paclitaxel treatment in ovarian cancer drug sensitivity analysis.
SNX1 is significantly downregulated in ovarian cancer tissues.
SNX1 overexpression inhibits ovarian cancer cell proliferation and blocks G1/S transition.
SNX1 overexpression promotes apoptosis in ovarian cancer cells.
SNX1 overexpression suppresses ovarian cancer cell migration and shifts EMT markers toward an epithelial state, with increased E-cadherin and decreased N-cadherin, vimentin, Snail1, and beta-catenin.
SNX1 overexpression is associated with downregulation of E2F1, CDK2, CDK6, and cyclin D1 during G1/S blockade in ovarian cancer cells.
SNX1 downregulation in ovarian cancer is linked by gene set enrichment analysis to activation of p53 signaling, PI3K/AKT signaling, E2F targets, and G2/M checkpoint programs.
Low SNX1 expression is associated with poor overall and progression-free survival in ovarian cancer.
SNX1 acts as a tumor suppressor and potential therapeutic target in ovarian cancer.